Home Manufacturer fund International and domestic collaboration will improve India’s business prospects-Health News, Firstpost

International and domestic collaboration will improve India’s business prospects-Health News, Firstpost


COVID-19 has placed India in a very favorable position to engage in pharmaceutical cooperation fostering a wider global association.

COVID-19 (novel coronavirus infection) It clearly reminded me of the importance of uninterrupted access to medicines and health products. We assume that the capabilities and capabilities of the country’s pharmaceutical industry are very important in this regard.

The importance of the pharmaceutical industry goes beyond the perspective of public health. This can be easily understood from the comparative example. Pioneer industries of the modern generation, such as the automobile, attract large investments and create important jobs around the world. Just as the outlook for the industry is important to governments, businesses, and consumers, disruptions in the automotive supply chain are less of a concern than pharmaceutical and pharmaceutical supply chains. The country can survive car delivery delays, but cannot survive on essential drugs and health products.

Countries with insufficient pharmaceutical capacities in the region are at risk of not providing essential health commodities to populations in the following unforeseen challenges: COVID-19 (novel coronavirus infection) .. The challenges each country faces in this regard are evident in the global diversity of national immunization.

To date, most African countries have been unable to immunize more than a few percent of their population on average. In South and Southeast Asia, the average vaccinated population in most countries is less than 20 percent of the population. High-income Asia-Pacific countries such as Australia and New Zealand also immunize less than about a third of their populations. This contrasts with North America, Western Europe and Southern Europe, where countries are vaccinated. About two thirds Of their people.

Countries that do not produce vaccines in the country must rely on supplies from others to immunize the population. The World Health Organization (WHO) common pool of vaccines is insufficient to meet global demand. Therefore, it is not surprising that vaccination rates vary widely around the world.

Access to vaccines to limit the incidence of COVID-19 (novel coronavirus infection) This is one of the top priorities for all countries, and the role of global vaccine producers has become very important. India plays a very important role in this regard.

India, variously described as the ‘pharmacy of the world’, has strong local skills to manufacture final dose formulations, biologics (such as vaccines) and other health products (such as surgery). .. A major exporter of pharmaceuticals and vaccines to major world markets. As the world’s 11th largest exporter, India accounted for 2.6% of global pharmaceutical exports in 2019. In the same year, India was the seventh largest exporter of vaccines, accounting for 3.9% of global vaccine exports.

COVID-19 (novel coronavirus infection) Vaccines manufactured and distributed by Indian pharmaceutical companies such as the Serum Institute of India (SII), Barrat Biotech and Dr. Reddies Laboratories are widely deployed in India and several other countries to combat pandemics. to augment. More local vaccines will soon be available locally and around the world, including ZyCoV-D (a needle-free vaccine that can be given to children over 12 years old) by Biological E, Gennova Pharmaceuticals and Zydus Cadilla.

India’s excellence as a global vaccine supplier has a lot to do with the effective foreign cooperation of local pharmaceutical companies. The partnership between AstraZeneca and SII to produce the Cobishield vaccine is well known. Covishield is WHO approved for emergency use and is being tested in several countries. The Sputnik V vaccine, developed by the Russian National Institute of Gamalaya, is distributed in India by Dr. Reddies Laboratories in collaboration with the Russian Infrastructure Development Fund (RIDF).

Other co-vaccines are expected. These include the Johnson & Johnson vaccines manufactured by Biological E. This vaccine is a revolutionary product because it is the result of a vaccine partnership announced for production by the Quad Group in the United States, India, Japan and in Australia. We distribute vaccines in the vast Indo-Pacific region. Biopharmacy has partnered with Providence Therapeutics of Canada to manufacture this latest vaccine. Novavax, a US vaccine maker, has also partnered with SII to make vaccines in India.

Business-to-business (B2B) collaboration is essential to strengthen India’s ability to be a leading player in its efforts. COVID-19 (novel coronavirus infection) .. With this cooperation, there will be no shortage of vaccines in India in the country. Combining foreign financial, technical and marketing expertise with local R&D and manufacturing skills is the best strategy for India and some developing countries to ensure such security. This collaboration places India in a laudable position of strength to serve its own people and the world.

COVID 19 sparks new international cooperation for Indian pharmaceutical industry. The benefits of these collaborations are significant for India and partner countries which are home to affiliates of Indian pharmaceutical companies. These partnerships extend beyond vaccines to treatment COVID-19 (novel coronavirus infection) .. A notable example is Gilead’s voluntary licensing agreement with an Indian generic manufacturer for the manufacture of Remdesivir. COVID-19 (novel coronavirus infection) Patience; MSD (Merck, Sharpe & Dohme) is working to allow local production of Molnupiravir. The collaboration highlights the importance of cross-border collaboration for companies to protect access to essential medicines. In terms of the availability of raw materials, important inputs, technical capacities, scale of production, financial resources and distribution networks, no country is sufficiently national to bypass these partnerships.

In terms of greater economic resilience and self-sufficiency, partnerships in the pharmaceutical industry will go a long way in strengthening regional capacities. NOT. COVID-19 (novel coronavirus infection) In this regard, we have provided India with the right opportunities and opportunities. This partnership will allow India to maintain its excellence as the world’s leading vaccine producer. They also form the basis for India’s pharmaceutical industry to be at the forefront in manufacturing drugs for future treatments. COVID-19 (novel coronavirus infection) ..

Public health security, in addition to being a global concern, is of paramount concern to all nations. The fact that India and its main geopolitical allies, the United States, Japan, the United Kingdom, Australia and Canada have decided to work together to expand the global supply of health products is of strategic importance for the pharmaceutical industry. Watch sex: the world’s biggest democracies are working together COVID-19 (novel coronavirus infection) Pandemics and drugs will undoubtedly be the starting point for broader international partnerships between countries.

COVID-19 (novel coronavirus infection) India is in an excellent position to engage in pharmaceutical cooperation that promotes a broader global association. India must seize the opportunity because the best pharmaceutical companies in the world are ready to work with India. It could be an Indian moment that has a decisive impact on the health and security of the world.

The author is Principal Investigator and Research Director (Business and Economics) at the Institute of South Asian Studies, National University of Singapore.

International and domestic collaboration will improve India’s business prospects-Health News, Firstpost

Source Link International and Domestic Collaboration Will Improve India’s Business Prospects-Health News, Firstpost